Ashfield Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Ashfield Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$6.42M	Sell	90,339 -2,092	-2%	-$152K	0.54%	51
2022 Q2	$7.12M	Sell	92,431 -644	-0.7%	-$49K	0.55%	51
2022 Q1	$6.8M	Buy	93,075 +446	+0.5%	+$29.9K	0.44%	54
2021 Q4	$5.78M	Sell	92,629 -3,881	-4%	-$228K	0.37%	66
2021 Q3	$5.71M	Sell	96,510 -647	-0.7%	-$42.6K	0.41%	63
2021 Q2	$6.49M	Sell	97,157 -555	-0.6%	-$36.2K	0.46%	54
2021 Q1	$6.17M	Buy	97,712 +1,438	+1%	+$89.5K	0.49%	55
2020 Q4	$5.97M	Sell	96,274 -10,498	-10%	-$646K	0.48%	55
2020 Q3	$6.44M	Sell	106,772 -2,399	-2%	-$144K	0.58%	52
2020 Q2	$6.42M	Buy	109,171 +70,067	+179%	+$4.19M	0.63%	49
2020 Q1	$2.18M	Sell	39,104 -2,640	-6%	-$161K	0.27%	80
2019 Q4	$2.68M	Buy	41,744 +15,950	+62%	+$913K	0.27%	84
2019 Q3	$1.31M	Hold	25,794	–	–	0.14%	122
2019 Q2	$1.17M	Sell	25,794 -300	-1%	-$14K	0.12%	130
2019 Q1	$1.25M	Sell	26,094 -430	-2%	-$21.4K	0.14%	126
2018 Q4	$1.38M	Buy	26,524 +430	+2%	+$23.1K	0.18%	114
2018 Q3	$1.62M	Hold	26,094	–	–	0.18%	116
2018 Q2	$1.44M	Sell	26,094 -167	-0.6%	-$9.02K	0.18%	127
2018 Q1	$1.66M	Buy	26,261 +167	+0.6%	+$10.7K	0.22%	107
2017 Q4	$1.6M	Sell	26,094 -17	-0.1%	-$1.06K	0.21%	111
2017 Q3	$1.66M	Sell	26,111 -148	-0.6%	-$8.64K	0.22%	107
2017 Q2	$1.46M	Buy	26,259 +247	+0.9%	+$13.4K	0.2%	115
2017 Q1	$1.42M	Hold	26,012	–	–	0.2%	120
2016 Q4	$1.52M	Sell	26,012 -50	-0.2%	-$2.73K	0.15%	120
2016 Q3	$1.41M	Buy	26,062 +148	+0.6%	+$9.51K	0.12%	125
2016 Q2	$1.91M	Hold	25,914	–	–	0.15%	108
2016 Q1	$1.66M	Sell	25,914 -653	-2%	-$41.2K	0.12%	121
2015 Q4	$1.83M	Sell	26,567 -1,598	-6%	-$106K	0.13%	119
2015 Q3	$1.67M	Sell	28,165 -943	-3%	-$59.8K	0.11%	122
2015 Q2	$1.94M	Hold	29,108	–	–	0.11%	122
2015 Q1	$1.88M	Sell	29,108 -1,111	-4%	-$69.6K	0.1%	125
2014 Q4	$1.78M	Sell	30,219 -4	-0%	-$226	0.09%	124
2014 Q3	$1.55M	Hold	30,223	–	–	0.08%	131
2014 Q2	$1.47M	Sell	30,223 -3,338	-10%	-$164K	0.07%	137
2014 Q1	$1.74M	Buy	33,561 +13,803	+70%	+$734K	0.08%	119
2013 Q4	$1.05M	Hold	19,758	–	–	0.05%	153
2013 Q3	$914K	Hold	19,758	–	–	0.05%	155
2013 Q2	$883K	Buy	+19,758	New	+$858K	0.05%	150

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ashfield Capital Partners's BMY Position: Q3 2022 in Review

Ashfield Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 2.3% in Q3 2022, selling an estimated $152K and leaving 90,339 shares worth $6.42M. The position accounts for 0.54% of the portfolio, ranked #51.

Ashfield Capital Partners first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $7.12M in Q2 2022. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

Ashfield Capital Partners held 90,339 shares of Bristol-Myers Squibb worth $6.42M as of Q3 2022.
Ashfield Capital Partners sold 2,092 Bristol-Myers Squibb shares in Q3 2022, an estimated $152K.
Bristol-Myers Squibb made up 0.54% of Ashfield Capital Partners's portfolio in Q3 2022, its #51 holding.
Ashfield Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
Ashfield Capital Partners's Bristol-Myers Squibb position peaked at $7.12M in Q2 2022.
2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.